Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
368
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. SpringWorks Therapeutics Inc market cap is $3.54B.
52 week high is the highest price of a stock in the past 52 weeks, or one year. SpringWorks Therapeutics Inc 52 week high is $62.00 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. SpringWorks Therapeutics Inc 52 week low is $28.21 as of November 22, 2026.
SpringWorks Therapeutics Inc stock price today is $46.99.
SpringWorks Therapeutics Inc stock price yesterday was $46.98.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. SpringWorks Therapeutics Inc's P/E ratio is -13.78.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. SpringWorks Therapeutics Inc P/B ratio is 8.4419.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. SpringWorks Therapeutics Inc 50-day moving average is $46.61.